ATR

AptarGroup, Inc. 2002 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2002. AptarGroup, Inc. is a leading global supplier of innovative dispensing systems (pumps, closures, and aerosol valves) for the personal care, fragrance/cosmetic, pharmaceutical, household, and food/beverage markets. The company operates through two reportable segments: Dispensing Systems (aggregating four business units) and SeaquistPerfect (focused on aerosol valves and pumps). The company has manufacturing facilities in North America, Europe, Asia, and South America, with approximately 56% of net sales generated in Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Record net sales were driven by growth in the personal care, pharmaceutical, household, and food/beverage markets, offsetting a decline in the fragrance/cosmetic sector due to weak economic conditions and inventory reductions by customers.
• Cost Pressures: Cost of sales as a percentage of net sales increased to 64.1% (from 63.1%) due to underutilized fixed costs in Europe, rising insurance premiums (up ~$2.5 million), and pricing pressure. However, cost reduction efforts and productivity gains partially offset these factors.
• Unusual Items: The 2002 results included a $4.2 million pre-tax charge for a patent dispute settlement and $1.2 million in Strategic Initiative charges (severance and benefits). In 2001, Strategic Initiative charges were significantly higher at $7.6 million, primarily due to asset impairments.
• Segment Performance: The SeaquistPerfect segment saw a significant improvement in EBIT, rising to $11.1 million (6.8% margin) from $5.8 million (4.0% margin) in 2001, driven by volume growth and a shift toward higher-margin custom products.
• Balance Sheet: The company strengthened its liquidity position, increasing cash by $42.2 million and reducing total interest-bearing debt. Net debt to net capitalization improved to 18.7% from 30.4%.

Guidance, Outlook, and Risks

• 2003 Outlook: Management expects diluted earnings per share for the first quarter of 2003 to range from $0.48 to $0.53. The company anticipates continued growth in the food/beverage market and new product introductions in personal care and household sectors.
• Pharmaceutical Market: Weakness in the pharmaceutical market observed in Q4 2002 (due to customer inventory corrections) is expected to persist into Q1 2003 but improve gradually.
• Currency Impact: A strengthening Euro relative to the U.S. dollar provides a positive translation effect on financial statements but negatively impacts operating margins on products imported from Europe to the U.S.
• Raw Materials: Resin prices are expected to increase in 2003, which could negatively impact results if cost pass-through to customers is delayed.
• Risks: Key risks include the impact of geopolitical instability (Middle East) on travel and duty-free sales, potential shortages of FDA-approved plastic resins for pharmaceutical products, and the high fixed-cost nature of the business which limits the ability to quickly reduce costs during demand downturns.

Investor Verification Checklist

• Patent Settlement: Verify the long-term impact of the $4.2 million patent dispute settlement and the terms of the cross-license agreement.
• Goodwill Impairment: Review the sensitivity analysis regarding the $128.9 million goodwill balance; management notes that a 25% reduction in cash flow estimates for one reporting unit could trigger a significant impairment charge.
• Foreign Currency Exposure: Assess the net impact of the strengthening Euro on future margins, given the company is a net importer of European-produced goods into the U.S.
• Insurance Costs: Monitor the trajectory of insurance premiums and self-insured retentions, which rose sharply in 2002.
• Strategic Initiative Completion: Confirm that no further charges are expected from the Strategic Initiative, which was declared essentially complete as of December 31, 2002.